Gutiérrez-Grobe Ylse, Bahena-Gonzalez Jose Antonio, Herrera-Gomar Magali, Mendoza-Diaz Pedro, García-López Sandra, González-Chon Octavio
Internal Medicine Department, Medica Sur Clinic and Foundation, Puente de Piedra No. 150, Colonia Toriello Guerra, Delegación Tlalpan, 14050 Mexico City, Mexico.
Case Rep Emerg Med. 2013;2013:634174. doi: 10.1155/2013/634174. Epub 2013 Aug 20.
Background and Aim. Levetiracetam is a second-generation antiepileptic drug. It is approved as an adjunctive treatment of partial onset seizures with or without secondary generalization. It is considered safe with less than 1% of patients with transient elevations of liver enzymes. Methods. We report a case of acute liver failure secondary to Levetiracetam in combination with Lacosamide documented with a liver biopsy. Results. Liver biopsy demonstrated acute liver injury with a predominant submassive necrosis pattern and features of a drug-induced hepatitis. Conclusions. This is the first published case of acute liver failure due to antiepileptic therapy with Levetiracetam in combination with Lacosamide.
背景与目的。左乙拉西坦是一种第二代抗癫痫药物。它被批准作为伴有或不伴有继发性全面发作的部分性发作的辅助治疗药物。据认为其安全性良好，肝酶短暂升高的患者比例不到1%。方法。我们报告一例左乙拉西坦联合拉科酰胺导致急性肝衰竭的病例，并通过肝活检证实。结果。肝活检显示急性肝损伤，主要为亚大块坏死模式及药物性肝炎特征。结论。这是首例关于左乙拉西坦联合拉科酰胺抗癫痫治疗导致急性肝衰竭的病例报道。
